CenTrial Logo

Impact of OPT-302 on Patients With Neovascular Age-Related Macular Degeneration


Clinical trial confirms OPT-302 treatment improves vision for macular degeneration patients

Neovascular Age-Related Macular Degeneration (nAMD) is a progressive eye condition affecting older adults, especially those over 50. It occurs when abnormal blood vessels grow beneath the macula, the central part of the retina, causing vision loss. This growth is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability.

Symptoms include distorted or blurry central vision, making reading and recognizing faces challenging. nAMD is a leading cause of severe vision impairment and blindness in developed countries. Although the exact cause is unknown, genetics, age, and smoking increase the risk. Treatments like anti-VEGF injections and photodynamic therapy can help slow its progression, but early detection and regular eye check-ups are crucial for better management.

Clinical Trial

A phase 2b clinical trial was conducted to test the safety and efficacy of a biologic inhibitor called OPT-302, which targets VEGF-C and D. Participants with nAMD were enrolled from various locations and randomized to receive different treatments. The primary outcome measured was the best-corrected visual acuity (BCVA) change at 24 weeks. Secondary outcomes included the proportion of participants with significant BCVA improvements or declines, changes in retinal thickness, and fluid accumulation. Three hundred and sixty-six participants were recruited and received either 0.5 mg or 2.0 mg OPT-302 or a sham treatment combined with intravitreal ranibizumab.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


The 2.0 mg OPT-302 group had significantly better visual acuity gains than the sham group. The 0.5 mg OPT-302 group did not differ significantly from the sham group. Structural outcomes also favored both OPT-302 dosage groups. Adverse events were similar across groups, and serious AEs were rare.


The combination therapy with 2.0 mg OPT-302 and ranibizumab was more effective in improving vision than the standard nAMD treatment. The treatment also showed good safety profiles. Further research and trials may be needed to validate and optimize this promising therapy for nAMD.
Opthalmology, Jun-23
ClinicalTrials.gov NCT03345082

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.